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Abstract
Purpose: To investigate the value of pre-operative contrast-enhanced MR
imaging (CE-MRI) in predicting the disease-free and overall survival in breast
cancer.
Material and Methods: The study population consisted of 50 consecutive
patients with histopathologically verified primary breast cancer who pre-
operatively underwent CE-MRI examination between 1992 and 1993. A three-
time pointMR examination was performed where the enhancement rates (C1 and
C2), signal enhancement ratio (SER¼C1/C2) and washout (W¼C1–C2) were
calculated. The relation of these MR parameters to disease-free and overall
survival was investigated. The median follow-up for surviving patients was
95months. Univariate and multivariate statistical analyses were performed to
evaluate the impact of different factors on prediction of survival.
Results: Of the MR parameters examined at univariate analysis, increased
C1 (p¼ 0.029), W (p¼ 0.0081) and SER values (p¼ 0.0081) were significantly
associated with shorter disease-free survival, and only C1 (p¼ 0.016) was related
significantly to overall survival. Multivariate analysis for disease-free survival
showed that the SER (p¼ 0.014) and tumor size (p¼ 0.001) were significant and
independent predictors. Age (p¼ 0.003), lymph node status (p¼ 0.014), tumor
size (p¼ 0.039) and proliferating cell nuclear antigen index (p¼ 0.053) remained
independently associated with overall survival at multivariate analysis. C1 was
not confirmed as an independent predictor of overall survival.
Conclusion: Our findings support the presumption that CE-MRI is useful in
predicting the disease-free survival in patients with breast cancer.
The conventional TNM classification system for
staging of breast cancer is widely used to determine
treatment and provides prognostic information (1).
The pre-operative staging is based on a combination
of clinical and imaging findings and includes the
assessment of tumor extent, multifocality and
lymph node status. Mammography and breast ultra-
sonography, however, often underestimate the extent
of the disease. MR imaging has been introduced as a
complementary diagnostic tool for the detection of
breast cancer. It is widely accepted that MR imaging
can reveal mammographically occult breast malig-
nancy, and has the ability to determine tumor size
and excludemultifocalitymore accurately than stand-
ard breast imaging methods (2). Recently, MR
imaging has also been suggested for pre-operative
loco-regional staging, as well as for the evaluation
of response to preoperative chemotherapy (8, 14).
Although staging is very important in the clinical
management and contains information on tumor
size and nodal involvement, treatment planning
and prediction of prognosis cannot be made
without the assessment of other postoperative
morphologic variables such as histologic type and
malignancy grade. Besides these classic prognostic
factors, a number of biological markers have also
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been suggested to predict the clinical outcome of
breast cancer (5).
In cancers other than breast cancer, it has been
shown that dynamic contrast-enhanced MR
imaging (CE-MRI) can contribute not only to
establish the diagnosis, but also to identify patients
with a poorer prognosis. Pharmacokinetic dynamic
MR imaging was found to be a predictor of disease-
free survival in pediatric osteosarcoma (15). It has
also been shown that MR imaging is able to assess
tumor aggressiveness and offers information on the
risk of local recurrence and on prediction of treat-
ment success in cervical cancer (9, 12). Recent reports
have demonstrated a correlation between MR
findings and prognostic indicators in breast cancer
(3, 13, 16). However, there is no evidence to support
the prognostic value of MR imaging concerning
survival data in patients with breast cancer.
The purpose of our study was to investigate the
value of pre-operative CE-MRI in predicting
recurrence free and overall survival of breast cancer.
We therefore evaluated the impact of different MR
enhancement parameters on survival rates and
compared it with established classic and molecular
prognostic markers.
Material and Methods
Patients: In 1998, we published a study on 50
consecutively investigated breast cancer patients that
had pre-operatively undergone CE-MRI between
September 1992 and December 1993 (3). Inclusion
criteria were a histopathologically verified primary
breast malignancy, and detectable abnormality at
MR imaging. The lesion had to be visible on MR on
at least three consecutive images to avoid a partial
volume effect when measuring the enhancement. This
previous study was focused on the correlation of MR
enhancement features and prognostic factors.We now
decided to followup on the disease-free interval and on
survival in these patients and correlate this with differ-
ent enhancement parameters derived from the MR
measurements. The hospital medical records of the
entire study population were reviewed, and disease-
free and overall survival was calculated. The median
follow-up for surviving patients was 95months (range,
23–111months). The mean age of the patients at the
diagnosis was 59 years (range, 29–83years).
CE-MRI (1992–93): A three-time point examin-
ation was performed with one precontrast and two
postcontrast series obtained 30 s to 7min and 7 to
13min, respectively, after the start of contrast agent
injection, using a T1-weighted 3D fast low angle shot
(FLASH) sequence on a 1.5 T system. Gd-DTPA was
administered at a dose of 0.1mmolkg1 body weight.
The enhancement rates (C1 and C2) were calculated for
the two postcontrast measurements. These parameters
show the relative increase in signal intensity to the
precontrast phase:
C1 ¼ SI1  SIpre
SIpre
 100 C2 ¼ SI2  SIpre
SIpre
 100
where C1 and C2 are the early and late contrast
enhancement ratios, SIpre is the precontrast, and
SI1 and SI2 are the first and second postcontrast
signal intensities.
The washout (W) and signal enhancement ratio
(SER) were also analyzed in this study. W was
defined as the difference between the first and second
enhancement rates:
W ¼ C1  C2
The SER method calculates the ratio of early-to-
late contrast enhancement, using the following
equation:
SER ¼ SI1  SIpre
SI2  SIpre ¼
C1
C2
This single parameter was used to describe the
contrast agent kinetics for three-time point, high-
resolution MR imaging in a study conducted by
ESSERMAN et al. (6).
The effect of the enhancement rates (C1 and C2),
W and SER variables on survival was investigated
in this present study.
Histopathologic analysis: All surgically excised
specimens were histopathologically examined. A ser-
ies of pathologic features such as tumor size, axillary
lymph node status, histologic type, mitotic count and
nuclear grade were assessed. Data were also collected
on the following biological markers: proliferating
cell nuclear antigen (PCNA), factor VIII (FVIII),
and CD 34.
The detailed morphologic analysis, immunohisto-
chemical and microvessel counting methods have
been described previously (3).
Statistical analysis: Disease-free survival was
defined as the time interval between the primary
operation and the local recurrence or metastasis or
the last follow-up. Overall survival was the period
from surgery until the date of death or the closure of
the study. All observations of surviving patients and
of those who died due to other causes than breast
cancer were censored. Univariate survival analysis
was based on the Kaplan-Meier product-limit method,
and survival curves were compared using the
log-rank test. The method described by HOTHORN &
LAUSEN (10) was used for the estimation of cut-points
for continuous predictor variables. The maximally
selected rank statistic for cut-points was calculated
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using the Maxstat software package for the R
statistical language and environment (R 1.5.1 for
Windows) (11).
Factors found to be significant at the univariate
test were then selected for multivariate analysis. Cox
proportional hazards regression was used for multi-
variate analysis to explore the relationship between
prognostic factors. A p-value of less than 0.05 was
considered as statistically significant. Univariate and
multivariate statistical analyses were performed
using the SPSS 9.0 for Windows (Statistical Package
for Social Sciences, SPSS).
Results
Patient age and histopathologic characteristics of
the lesions are summarized in Table 1.
The cumulative 5-year and 7-year survival rates for
the whole cohort was 63% and 59% for disease-free,
81% and 77% for overall survival, respectively. Local
recurrence or metastasis of the primary disease devel-
oped in 20 (40%) patients. Until the last check-up, 15
(30%) patients had died: 11 (22%) women died from
breast cancer, and 4 (8%) patients from other causes.
Cut-point estimation: The cut-points of continuous
variables that provide an optimum separation of
patients into two groups with different survival
times were estimated using the maximally selected
rank statistics. The cut-off points of quantitative
MR enhancement parameters for disease-free/overall
survival were the following: 226/238 for C1, 130.34/
132.35 for C2, 1.79/11.65 for W and 1.008/1.028 for
SER. Figure1 shows the standardized log-rank
statistic as a function of the selected cut-point of
SER for disease-free survival.
Analysis of disease-free survival: Table 2 shows the
result of the univariate analysis. Among the different
variables, C1, W, SER, tumor size, nuclear grade and
the PCNA index were the statistically significant
predictors of recurrence or metastasis. C2, patient
age, nodal status, microvessel and mitotic counts
had no significant impact on disease-free interval.
Figures 2 and 3 show the Kaplan-Meier estimates
of disease-free survival according to the MR
enhancement parameters C1 and SER.
For disease-free survival, C1, W, SER, tumor size,
nuclear grade and the PCNA index were entered into
a Cox proportional hazards regression model. Only
SER and tumor size were found to be significant and
independent prognostic factors of disease-free sur-
vival. C1, W, the PCNA index and nuclear grade
were rejected from the final regression model (Table3).
Analysis of overall survival: Assessing the effects of
different parameters on overall survival, C1, age,
tumor size, nodal involvement, nuclear grade and
the PCNA index were found to be significant at
univariate analysis. C2, W, SER, microvessel and
mitotic counts failed to predict the overall survival
in our patient cohort (Table 2).
Kaplan-Meier curves for overall survival, accord-
ing to the MR enhancement parameters C1 and
SER are shown on Figs 4 and 5.
C1, age, tumor size, lymph node status, nuclear
grade and the PCNA index were analyzed for over-
all survival in the second regression model. Age,
lymph node status, tumor size and the PCNA
index retained independent prognostic significance.
C1 and nuclear grade were not significant (Table 4).
Discussion
To our knowledge, this paper is the first report that
explores the prognostic significance of MR contrast
enhancement in breast cancer using statistical
methods of survival analysis. The result of our
Table 1
Patient age and histopathologic characteristics in 50 patients
undergoing CE-MRI from 1992 to 1993
Parameters n ¼ 50 %
Age
50 12 24
>50 38 76
Tumor size
2 cm 26 52
>2 cm 24 48
Histologic type
Ductal 32 64
Lobular 8 16
Other 10 20
Nuclear grade
High 23 46
Low 27 54
Lymph node status
Positive 17 34
Negative 30 60
Data missing 3 6
PCNA*
43 37 74
>43 13 26
Factor VIII*
81 38 76
>81 10 20
Data missing 2 4
CD-34*
55 11 22
>55 33 66
Data missing 6 12
Mitotic count*
1 17 34
>1 33 66
*Cut-off points were calculated for overall survival by using the method
of HOTHORN and LAUSEN (10). PCNA: proliferating cell nuclear antigen
immunoreactivity; Factor VIII: microvessel count using factor
VIII immunostaining; CD-34: microvessel count using CD-34 immuno-
staining.
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study demonstrates that SER measured by CE-
MRI using the three-time point temporal resolution
is a significant and independent prognostic factor
for the disease-free period in breast cancer patients.
Although tumor size was found to be the strongest
predictor for disease-free survival, the prognostic value
of SER was superior to established prognostic factors
such as nuclear grade and the PCNA index. On the
univariate analysis, a significant difference in disease-
free and overall survival was observed for the first
enhancement variable (C1). Washout (C1–C2) was
also significant for disease-free survival. These MR
parameters, however, were rejected from the Cox
regression models at multivariate analysis, and an
explanationmight be that the sample sizeof ourpatient
population was relatively small to assess their real
prognostic relevance. The second enhancement rate
(C2) failed to show any association with patients’
survival times.
Signal intensities were measured at three-time
points to obtain kinetic information on MR
contrast agent uptake in this study. The enhance-
ment rates (C1 and C2) show the increase in signal
intensity at postcontrast measurements compared
with the precontrast values. Early enhancement
(C1) is often referred to as the ‘‘washin’’ phase,
while C2 is commonly used to obtain kinetic infor-
mation. The degree of ‘‘washout’’ can be shown by
the difference between C1 and C2.
Table 2
Univariate analysis on MR parameters and known prognostic
factors in 50 patients with breast cancer
Parameters 1p-value for
disease-free survival
1p-value for
overall survival
C1 0.029* 0.016*
C2 0.54 0.073
W 0.0081* 0.067
SER 0.0081* 0.089
Age 0.36 0.011*
Tumor size 0.0073* <0.0001*
Nodal status 0.064 0.0042*
Nuclear grade 0.024* 0.049*
PCNA 0.0009* <0.0001*
Factor VIII 0.17 0.12
CD-34 0.12 0.17
Mitotic count 0.12 0.067
1p-values estimated using the log-rank test. *Variables selected formulti-
variate analysis (p< 0.05). C1, C2: first and second enhancement rates at
CE-MRI;W: washout (W¼C1–C2). Other abbreviations as in Table 1.
Fig. 2. Disease-free survival as a function of the early enhancement
rate (C1) at CE-MRI in 50 patients with breast cancer. The difference
between the survival curves was significant (log-rank test, p¼ 0.029).
Fig. 1. Standardized log-rank statistics as a function of the chosen
cut-point for the SER. The estimated cut-point is 1.008 for SER
examining the disease-free survival time. Note – standardized log-
rank statistics based on the upper bound of the p-value according to
HOTHORN & LAUSEN (10).
Fig. 3. Disease-free survival as a function of SER (SER¼C1/C2) at
CE-MRI in 50 patients with breast cancer. The difference between
the survival curves was significant (log-rank test, p¼ 0.0081).
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The SER analysis (6) has the ability to characterize
both ‘‘washin’’ and ‘‘washout’’ in a single parameter.
High SER values represent early enhancement and
washout, while low SER values indicate slow enhance-
ment and absence of washout. In this context, it is
quite interesting that the threshold of SER¼ 1 (when
C1 and C2 are equal) provides the best separation of
patients with enhancing lesions into two prognostic
groups (Fig. 1), and the group of lesions with SER
values higher than 1 (quick enhancement and wash-
out) represents the high-risk part of the population
(Fig. 3).
Our previous study on the same patient material
(3) reported a correlation between enhancement
kinetics and established morphologic and molecular
prognostic factors. Thus, MR enhancement was
associated with the PCNA index and angiogenesis
assessed by FVIII and CD-34. There was also a
correlation between contrast enhancement and
nuclear grade. Because recurrence free and overall
Table 3
Multivariate analysis* for disease-free survival in 50 patients with breast cancer
Parameters Hazard ratio
[exp (b)]
Regression
coefficient (b)
Standard error
for b
95% confidence
interval for
exp (b)
p-value
SER 11.79 2.47 1.00 1.66–83.84 0.014
Tumor size 1.08 0.08 0.03 1.03–1.15 0.001
C1, W, PCNA and nuclear grade were rejected from the regression model. *Cox proportional hazards regression analysis was performed with
the forward covariate selection method. Abbreviations as in Tables 1 and 2.
Fig. 4. Overall survival as a function of C1 at CE-MRI in 50
patients with breast cancer. The difference between the survival
curves was significant (log-rank test, p¼ 0.016).
Fig. 5. Overall survival as a function of SER at CE-MRI in 50
patients with breast cancer. The difference between the survival
curves was not significant (log-rank test, p¼ 0.089).
Table 4
Multivariate analysis* for overall survival in 50 patients with breast cancer
Parameters Hazard ratio
[exp b]
Regression
coefficient, b
Standard error
for b
95% confidence
interval for
exp, b
p-value
Age 1.10 0.10 0.03 1.03–71.17 0.003
Lymph node status 5.89 1.77 0.72 1.44–24.06 0.014
Tumor size 1.07 0.07 0.03 1.00–1.14 0.039
PCNA 1.09 0.09 0.05 1.00–1.20 0.053
C1 and nuclear grade were rejected from the regression model. *Cox proportional hazards regression analysis was performed with the forward
covariate selection method. Abbreviations as in Tables 1 and 2.
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survival times were found to be significantly shorter
in patients with strong MR contrast enhancement,
this study seems to verify our preliminary assump-
tion that there is an association between the extent
of MR contrast uptake and breast cancer prognosis.
In addition, our earlier findings are in agreement
with other studies. MUSSURAKIS et al. compared MR
enhancement ratios with different histopathological
prognostic factors (13), and found a strong associ-
ation with lymph node status and histologic grade.
STOMPER and colleagues reported an association
between cell proliferating activity assessed by
DNA S-phase percentage and peripheral MR
enhancement pattern (16).
Our findings that tumor size, lymph node status and
PCNAindexare independent prognostic indicators are
in accordance with previous larger studies (4, 17). In
spite of the findings in our previous investigations,
when the grade of angiogenesis was statistically related
to the enhancement parameters, neither FVIII- nor
CD-34-based vessel counts showed any association
with disease-free and overall survival in the present
study. This supports the view that morphologic evalu-
ation of vascular density often fails to demonstrate an
association with patients’ survival due to the vascular
heterogeneity of tumors (7).
There are recent studies focusing on the prognostic
value of MR parameters in other types of malignant
tumors. REDDICK et al. investigated the impact of a
pharmacokinetic CE-MRI model on disease-free
survival in pediatric osteosarcoma (15). The modeled
exchange rate of the contrast agent between the
vascular bed and extracellular space (e.g., vascular
permeability) was highly predictive for the patients’
disease-free period. According to their results, MR
imaging has been proved to be an independent pre-
dictive factor in osteosarcoma after pre-operative
chemotherapy. A study of MAYR et al. (12) showed
that MR perfusion examinations might offer import-
ant information on treatment outcome in advanced
cervical cancer. HAWIGHORST et al. (9) assessed the
angiogenic activity of cervical cancer by conventional
morphologic methods, and compared them with
pharmacokinetic MR imaging. They found that
functional MR parameters predicted the patients’
survival, rather than did morphologic microvessel
counts.
In conclusion, the result of this study suggests that
CE-MRI can predict disease-free survival and is not
only important for pre-operative diagnosis and
staging, but may also be useful as a prognostic tool
for the evaluation of patients with breast cancer.
Despite our relatively small sample size, an association
was also seen between MR enhancement and overall
survival. On the basis of this promising result, further
large-scale studies are needed to examine the impact of
MR enhancement on the prediction of long-term over-
all survival.
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